Brief: Tela Bio Announces U.S. Commercial Launch Of Liquifix – The Only FDA-Approved Liquid Adhesive For Internal Use In Hernia Surgery
21/03/2024 11:37
March 21 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO ANNOUNCES U.S. COMMERCIAL LAUNCH OF LIQUIFIX™ –
THE
ONLY FDA-APPROVED LIQUID ADHESIVE FOR INTERNAL USE IN HERNIA
SURGERY
Source text for Eikon: ID:nGNX6q0Nfw
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsTELA Bio Q1 revenue growth beats estimates, loss widens
Brief: TELA Bio Q1 Revenue USD 19.059 Million Vs. IBES Estimate USD 18.6 Million
Brief: Tela Bio Announces Inducement Grants Under Nasdaq Listing Rule
Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly
Brief: TELA Bio Announces Pricing Of $13.0 Million Underwritten Registered Direct Offering Of Common Stock And Pre-Funded Warrants